Table 1 Clinical features of study cohort.

From: Morphologic and immunohistochemical features of carcinoma involving microglandular adenosis of the breast following neoadjuvant chemotherapy

Case

Age (years)

Imaging size (cm)

Physical exam findings

Neoadjuvant therapy regimen

Procedure

TNBC at Excision

MGAa size (cm)

Lymph node status

Follow-up (months)

1

49

3.5

Palpable mass

ACT

BCS, SLNB

No

2.7

0/6

NED (37)

2

77

0.9

No abnormality

CMF

BCS

No

1.1

ND

NED (7)

3

46

3.5

Palpable mass

ACT

BCS, SLNB

No

2.7

0/8

NED (20)

4

32

2.2

Palpable mass

ACT

BCS, SLNB

Yes (0.2 cm)

2.2

0/5

NED (8)

5

40

2.0

Palpable mass

ACT

Mast, SLNB

No

2.3

0/4

NED (45)

6

29

N/A

N/A

Unknown

Mast, ALND

Yes (6.5 cm)

1.8

1/1

N/A

7

44

3.1

N/A

ACT

Mast, SLNB

No

1.5

0/4

NED (8)

8

57

2.3

Area of fullness

ACT

Mast, SLNB

No

2.3

0/11

NED (14)

9

57

3.1

Palpable mass

ACT

Mast

No

3.0

0/4

NED (1)

10

56

1.0

Palpable mass

ACT

BCS, SLNB

Yes (0.3 cm)

2.2

0/2

NED (1)

11

43

2.3

Palpable mass

ACT

Mast, ALND

Yes (3 cm)

0.5

2/21

AWD (30)

12

29

3.2

Palpable mass

ACT

Mast, SLNB

No

1.5

0/2

NED (4)

  1. ACT anthracyclines and taxanes, CMF cyclophosphamide methotrexate fluorouracil, TNBC triple negative invasive breast cancer, BCS breast conservation surgery, SLNB sentinel lymph node biopsy, Mast mastectomy, ALND axillary lymph node dissection, N/A not available, ND not done, NED no evidence of disease, AWD alive with disease.
  2. aMGA microglandular adenosis, atypical microglandular adenosis and/or carcinoma involving microglandular adenosis.
Back to article page